Access

Research Highlights

Nature Reviews Nephrology 3, 642–643 (1 December 2007) | doi:10.1038/ncpneph0630

Homocysteine lowering does not improve survival in advanced CKD or ESRD

Jamison RL et al. (2007) Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298: 1163–1170 High plasma homocysteine levels have been associated with an increased risk for cardiovascular disease, but randomized trials of homocysteine-lowering therapies have reported conflicting results.